Novo Nordisk: Buying the Panic - A Contrarian Trade After the Big Reset
Novo Nordisk ($NVO) has been hammered to the mid-$40s after a year of pricing and competitive concerns. The selloff has pushed the stock to a single-digit P/E near 10x and a market cap of about $204 billion. Management is buying shares back and core obesity/diabetes demand remains sizable. This trade idea proposes a buy at $46.50, with a $42.00 sto…